Loading…
10x Genomics, Inc. is projected to rise to $31.21 by 2027, a +22% move from its current price of $25.51. TXG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $24.71 | $25.53 | $26.37 | +0.06% |
| May 30 | $24.39 | $25.54 | $26.75 | +0.13% |
| May 31 | $24.16 | $25.56 | $27.04 | +0.19% |
| Jun 1 | $23.96 | $25.58 | $27.30 | +0.26% |
| Jun 2 | $23.79 | $25.59 | $27.53 | +0.32% |
| Jun 3 | $23.64 | $25.61 | $27.74 | +0.39% |
| Jun 4 | $23.51 | $25.62 | $27.93 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $23.51 | $25.62 | $27.93 | +0.45% |
| Week 2 | $22.78 | $25.74 | $29.08 | +0.90% |
| Week 3 | $22.27 | $25.86 | $30.02 | +1.36% |
| Week 4 | $21.86 | $25.97 | $30.86 | +1.81% |
| Week 5 | $21.51 | $26.09 | $31.64 | +2.27% |
| Week 6 | $21.21 | $26.21 | $32.37 | +2.73% |
| Week 7 | $20.95 | $26.33 | $33.08 | +3.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. Its portfolio includes the Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
It also offers Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, it offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents.
Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions.
TXG current price is $25.51 and has a market cap of $3.24B, with a market rank of 1650. It operates in the Healthcare category and is subject to the dynamics of its sector. The forecast implies a path for price from a 2026 average of $25.51 toward higher values in subsequent years, including a 2030 average of $57.06, a 2040 average of $128.58, and a 2050 average of $299.96.
The corresponding max prices for those years are $86.52 (2030), $230.80 (2040), and $595.20 (2050). These projections carry associated ROIs of 123.7% by 2030, 404.1% by 2040, and 1075.9% by 2050, with a bullish tilt developing after 2026 (2026 is neutral). The current price aligns with the forecasted 2026 average, reflecting a starting point at $25.51 for the coming years.
A major floor 34.6% below — a decisive break under it would weaken the trend.
The nearest floor, 20.8% below — buyers have tended to step in here.
Price is pressing into resistance (2.2% away) — a breakout level to watch.
A major ceiling 16.9% above — clearing it would confirm fresh momentum.
Key TXG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TXG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.49 | Buy | $24.35 | Buy |
| MA 10 | $23.00 | Buy | $23.52 | Buy |
| MA 20 | $22.33 | Buy | $22.88 | Buy |
| MA 50 | $21.99 | Buy | $22.06 | Buy |
| MA 100 | $21.06 | Buy | $20.74 | Buy |
| MA 200 | $17.73 | Buy | $18.82 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.45 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 185.35 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.40 | Buy |
| ROC (12) | 18.10 | Buy |
| Bollinger %B (20,2) | 1.06 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | 1.69 | Buy |
| Ultimate (7,14,28) | 73.60 | Sell |
| Momentum (10) | 4.59 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 25.36 | Buy |
| ADX (14) | 14.22 | Neutral |
| ATR (14) | 0.76 | Info |
The 30-day technical picture shows a bullish sentiment with RSI(14) at 60 and moving averages near the level of the price. The SMA50 stands at $21.99 and the SMA200 at $17.73, providing near-term support and longer-term context. The current near-term support is at $20.20 with resistance at $26.08, and the 30-day price range stretches from $20.58 to $31.63, indicating consolidated action within a defined band.
Annualized volatility is around 60%, underscoring notable price variability within shorter horizons.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.62 | $25.51 | $34.12 | 0% | Neutral | |
| $24.29 | $31.21 | $42.76 | +22% | Bullish | |
| $29.12 | $38.68 | $55.24 | +52% | Bullish | |
| $33.21 | $45.37 | $66.93 | +78% | Bullish | |
| $40.75 | $57.06 | $86.52 | +124% | Bullish | |
| $43.57 | $62.41 | $96.94 | +145% | Bullish | |
| $43.63 | $63.85 | $101.33 | +150% | Bullish | |
| $48.35 | $72.21 | $116.85 | +183% | Bullish | |
| $46.86 | $71.35 | $117.53 | +180% | Bullish | |
| $53.68 | $83.25 | $139.43 | +226% | Bullish | |
| $76.15 | $128.58 | $230.80 | +404% | Bullish | |
| $152.80 | $299.96 | $595.20 | +10.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $16.62 | $25.51 | $30.12 | +0.00% |
| June 2026 | $22.67 | $26.74 | $32.37 | +4.83% |
| July 2026 | $22.70 | $27.05 | $33.27 | +1.14% |
| August 2026 | $21.92 | $26.32 | $32.77 | -2.70% |
| September 2026 | $22.03 | $26.63 | $33.49 | +1.19% |
| October 2026 | $22.51 | $27.37 | $34.73 | +2.79% |
| November 2026 | $21.94 | $26.82 | $34.30 | -2.01% |
| December 2026 | $21.56 | $26.49 | $34.12 | -1.25% |
Click any year to see its month-by-month TXG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TXG to range from $16.62 to $34.12 through 2026. The $25.51 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TXG price prediction for 2027 points to an average of $31.21 (low $24.29, high $42.76) — a potential gain of +22% on today's $25.51. Buyers look set to stay in control over this stretch.
In 2028, TXG is projected to trade between $29.12 and $55.24, averaging $38.68 — a potential gain of +52% from today's $25.51. That is up +24% on the projected 2027 average. Momentum favours further upside here.
10x Genomics, Inc.'s 2029 outlook centres on $45.37, within a $33.21 to $66.93 range. That is up +17% on the projected 2028 average. That marks a +78% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, TXG could reach as high as $86.52, with a base case around $57.06 and support toward $40.75 — roughly +124% from $25.51. Momentum favours further upside here.
Expect TXG to range from $43.57 to $96.94 through 2031. The $62.41 average target implies a +145% move from current prices. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The TXG price prediction for 2032 points to an average of $63.85 (low $43.63, high $101.33) — a potential gain of +150% on today's $25.51. Momentum favours further upside here.
In 2033, TXG is projected to trade between $48.35 and $116.85, averaging $72.21 — a potential gain of +183% from today's $25.51. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
10x Genomics, Inc.'s 2034 outlook centres on $71.35, within a $46.86 to $117.53 range. That is -1% versus the projected 2033 average. That marks a +180% change versus current levels. Momentum favours further upside here.
By 2035, TXG could reach as high as $139.43, with a base case around $83.25 and support toward $53.68 — roughly +226% from $25.51. Buyers look set to stay in control over this stretch.
Expect TXG to range from $76.15 to $230.80 through 2040. The $128.58 average target implies a +404% move from current prices. That is up +54% on the projected 2035 average. Momentum favours further upside here.
The TXG price prediction for 2050 points to an average of $299.96 (low $152.80, high $595.20) — a potential gain of +10.8x on today's $25.51. Buyers look set to stay in control over this stretch.
Investing $1,000 in TXG today (≈ 39.200314 TXG) could be worth
$11,758.63
+$10,758.63 (+1076%) by 2050 · US Dollar
Based on the average projected TXG price of $299.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TXGwould be worth at today's price.
$1,000 invested in TXG on May 27, 2025 (≈ 116.414433 TXG) would be worth
$2,969.73
+$1,969.73 (+197.0%) today · 2.97× · US Dollar
Based on a TXG entry price of $8.59 vs. today's $25.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.98 | $1,063.8 | +6.4% |
| 1 month ago | $22.28 | $1,144.97 | +14.5% |
| 3 months ago | $22.13 | $1,152.73 | +15.3% |
| 6 months ago | $18.81 | $1,356.19 | +35.6% |
| 1 year ago | $8.59 | $2,969.73 | +197.0% |
| All time (5.0y) ago | $176.25 | $144.74 | -85.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TXG forecast.
Our base-case forecast reaches $51.00 around 2030.
Implied market cap at $51.00: $5.96B
The multi-year forecast paints a bullish trajectory across the horizon. In 2026 the expected average price is $25.51 with a neutral sentiment; by 2027 the average price rises to $31.21 (ROI 22.4%), by 2028 to $38.68 (ROI 51.6%), and by 2029 to $45.37 (ROI 77.8%). The 2030 average is $57.06 (ROI 123.7%), followed by 2031 at $62.41 (ROI 144.7%), 2032 at $63.85 (ROI 150.3%), 2033 at $72.21 (ROI 183.1%), 2034 at $71.35 (ROI 179.7%), and 2035 at $83.25 (ROI 226.3%).
The forecast continues higher with 2040 at an average of $128.58 (ROI 404.1%) and 2050 at an average of $299.96 (ROI 1075.9%), with a max of $86.52 in 2030, $230.80 in 2040, and $595.20 in 2050. These figures imply a progressively bullish outlook after 2026, though they are estimates and not guarantees. Investors should consider the potential for volatility and uncertainty inherent in long-range projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $57.06 with a min of $40.75 and a max of $86.52, and an ROI of 123.7%. The sentiment is BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with 2030, 2040, and 2050 avg prices of $57.06, $128.58, and $299.96 and ROIs of 123.7%, 404.1%, and 1075.9%, respectively, though 2026 is neutral and outcomes are not guaranteed.
Yes. The 2050 forecast lists an average of $299.96 and a max of $595.20, indicating a potential to approach or exceed $300 in the longer term.
$3.24B.
10x Genomics, Inc. Community Discussion
0Share your 10x Genomics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.